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We have evaluated protection against a genital Chlamydia trachomatis infection in a pig 
challenge model. Animals were immunized with a major outer membrane protein (MOMP)-based 
DNA vaccine carrying five pig-specific CpG motifs incorporated in the plasmid backbone 
(pWRG7079). Protection was promoted by administrating the porcine granulocyte macrophage-
colony stimulating factor (GM-CSF) and the Escherichia coli thermo-labile enterotoxin LT, 
which is an exceptionally potent mucosa-binding molecule, as adjuvants. Protection against 
genital C. trachomatis challenge through mucosal immunization (combined vaginal and nasal 
vaccine administration) was compared to systemic (intradermal) immunization. Mucosal 
vaccination resulted in significant protection characterized by less severe macroscopic lesions, 
less vaginal shedding of chlamydia and less bacterial replication in the urogenital tract of 
immunized pigs. Also, mucosal immunized pigs showed significantly higher proliferative 
responses of peripheral blood lymphocytes. Furthermore, the combination of nasal and vaginal 
immunization could induce serum antibody titers upon immunization and early upon challenge 
with C. trachomatis serovar E. However, the infection could not be eradicated. Systemic 
immunization was significantly less efficient at eliciting protection, which emphasizes the need 
for a mucosal vaccine in order to obtain significant protection against genital C. trachomatis 
infection.  
